Dr. Pietrantonio Filippo
Doctor
Contacts
- Mail: filippo.pietrantonio@istitutotumori.mi.it
- Mail: renata.spallone@istitutotumori.mi.it
- Tel: 02.23903822
Specialty / Department
- Medical Oncology
Dr. Pietrantonio is a medical oncologist and researcher affiliated with the Fondazione IRCCS Istituto Nazionale dei Tumori di MIlano since the beginning of his specialization in 2007.
His work focuses on the study and on the treatment of gastrointestinal cancers, including colorectal, stomach, esophageal, liver, biliary tract, pancreatic, and peritoneal tumors.
He is the author of over 350 scientific publications in international journals and has led numerous clinical studies involving new drugs and innovative strategies, as well as research projects on biomarkers for therapy response—some of which have received significant public or private funding.
He collaborates with leading oncological institutions worldwide and is recognized as one of the most active gastrointestinal oncologists globally.
His primary interest lies in the design of non-profit clinical trials that are not sponsored by pharmaceutical companies, aiming to improve clinical practice.
He is a member of the Executive Committee of the GONO Foundation, a non-profit organization that has developed several treatments currently recommended in international guidelines. He also serves on the Board of Directors of the Italian Association of Medical Oncology and is an active member of major international oncology scientific societies.
The team he leads consists of outstanding oncologists with strong potential for research growth, and he is focused on fostering the training of young oncologists and medical residents who will shape the future of the Foundation.
His research has significantly contributed to defining current treatment standards for various gastrointestinal cancers, including colorectal and gastroesophageal carcinoma.
- Mail: filippo.pietrantonio@istitutotumori.mi.it
- Mail: renata.spallone@istitutotumori.mi.it
- Tel: 02.23903822
Gastrointestinal Oncology
A Phase 1/2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of MK-2870 Plus Paclitaxel as the Second-Line Treatment of Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma:
A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers
A Phase 1/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers
A Phase 1b/2, multicenter, open-label study to evaluate the efficacy and safety of GSK5764227, alone or in combination with other treatments, in participants with previously treated, unresectable, or metastatic advanced
A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer (61186372GIC2002 – Origami 1)
A Phase 3, Multi-Center, Randomized, Open-Label Clinical Study of Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy as First-Line Treatment in Patients With Locally Advance
A phase II, open label, multicenter trial investigating Irinotecan plus cetuximab rechallenge compared with trifluridine/tipiracil plus bevacizumab as third line treatment in circulating tumor DNA molecularly selected me
ENGIC 01 (PRODIGE 107)– COLOSOTO
A single-arm phase II study evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib (KRAS G12C inhibitor) in first-line treatment of patients non-eligible for a doublet/trip
Gemcitabine plus nab-PAclitaxel as switch maiNTEnance versus cONtinuation of modified FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: the PANThEON phase III Trial
Last update: 01/09/2026